Leading the Charge: How the Private Sector is Advancing Alzheimer’s Diagnosis with Blood Biomarkers

While the Biomarker Challenge aims to bring blood tests to the NHS in five years, the most advanced test - granted FDA Breakthrough Device Designation - is already available privately in the UK. Learn how this affordable, non-invasive test drives early detection and new treatment monitoring.